Syndax Pharmaceuticals Inc SNDX

NAS: SNDX | ISIN: US87164F1057   30/04/2025
14,15 USD (+3,28%)
(+3,28%)   30/04/2025

6 september 2024 · Syndax Pharmaceuticals Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4) · Persbericht

12 augustus 2024 · Syndax Announces Publication in the Journal of Clinical Oncology of Data from the Pivotal AUGMENT-101 Trial of Revumenib in Relapsed/Refractory KMT2Ar Acute Leukemia · Persbericht

5 augustus 2024 · Syndax Pharmaceuticals Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4) · Persbericht

1 augustus 2024 · Syndax Reports Second Quarter 2024 Financial Results and Provides Clinical and Business Update · Persbericht

29 juli 2024 · Syndax Announces PDUFA Action Date Extension for Revumenib NDA for Relapsed or Refractory KMT2Ar Acute Leukemia · Persbericht

25 juli 2024 · Syndax to Announce Second Quarter 2024 Financial Results and Host Conference Call and Webcast on August 1, 2024 · Persbericht

5 juli 2024 · Syndax Pharmaceuticals Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4) · Persbericht

14 juni 2024 · Syndax Presents Updated Positive Data from BEAT AML and AUGMENT-102 Phase 1/2 Combination Trials of Revumenib in Patients with Acute Leukemias at EHA 2024 Congress · Persbericht

6 juni 2024 · Syndax Announces Plans to Advance into Phase 1b Portion of Trial Evaluating Revumenib in Relapsed or Refractory Metastatic MSS CRC · Persbericht

5 juni 2024 · Syndax Announces Participation at the Goldman Sachs 45th Annual Global Healthcare Conference · Persbericht

3 juni 2024 · Syndax Pharmaceuticals Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4) · Persbericht

15 mei 2024 · Syndax Pharmaceuticals Appoints Aleksandra Rizo, M.D., Ph.D. to the Board of Directors · Persbericht

9 mei 2024 · Syndax Announces Participation at the Bank of America Securities 2024 Health Care Conference · Persbericht

8 mei 2024 · Syndax Pharmaceuticals Reports First Quarter 2024 Financial Results and Provides Clinical and Business Update · Persbericht

3 mei 2024 · Syndax Pharmaceuticals Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4) · Persbericht

1 mei 2024 · Syndax to Announce First Quarter 2024 Financial Results and Host Conference Call and Webcast on May 8, 2024 · Persbericht

10 april 2024 · Syndax Announces Participation at the Stifel 2024 Virtual Targeted Oncology Forum · Persbericht

8 april 2024 · Syndax Presents Positive Pediatric Data from Pivotal AUGMENT-101 Trial of Revumenib in Relapsed/Refractory KMT2Ar Acute Leukemia at ASPHO Plenary Session · Persbericht

5 april 2024 · Syndax Pharmaceuticals Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4) · Persbericht

28 maart 2024 · Syndax Announces Completion of Enrollment in AUGMENT-101 Pivotal Trial Cohort of Patients with Relapsed/Refractory mNPM1 Acute Myeloid Leukemia · Persbericht

Mijn selecties